Literature DB >> 21906126

Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens.

Anne-Marie O'Shea1, Emad A Rakha, Zsolt Hodi, Ian O Ellis, Andrew H S Lee.   

Abstract

AIMS: Histological grade assessed on core biopsy of mammary invasive carcinomas tends to underestimate the grade in the excision specimen. A major factor is underestimation of mitoses. The aim of this study was to improve the assessment of mitoses in core biopsies. METHODS AND
RESULTS: In a test set (100 tumours), reducing the threshold for a mitotic score of 2 from 11 mitoses per 10 high-power fields (diameter 0.61 mm) to 6/10 resulted in improved agreement between core and excision from 69% to 73%. In tumours graded as T3 P3 M1 (few tubules, marked nuclear pleomorphism and few mitoses) on core (a group with poor agreement of grade between core and surgical specimens), this change in threshold also improved agreement in four tumours. Use of the mitotic count in the core of axillary nodal metastasis, if higher than the count in the breast core, improved agreement in two patients. Use of both approaches in a validation set (349 tumours) improved agreement from 65% to 70% in the whole group, and from 31% to 55% in tumours scored as T3 P3 M1 on the core.
CONCLUSIONS: These strategies improve the accuracy of grading on core biopsy and are of particular value in T3 P3 M1 tumours.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Year:  2011        PMID: 21906126     DOI: 10.1111/j.1365-2559.2011.03916.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].

Authors:  M Christgen; W Winkens; H H Kreipe
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

Review 2.  [Ki67: biological intertumor variance versus variance of assay].

Authors:  H Kreipe
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

3.  Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.

Authors:  Aswin Shanmugalingam; Kerry Hitos; Shrenik Hegde; Ali Al-Mashat; Nirmala Pathmanathan; Senarath Edirimmane; T Michael Hughes; Nicholas K Ngui
Journal:  Breast Cancer Res Treat       Date:  2022-02-28       Impact factor: 4.872

Review 4.  [Translational research and diagnostics for breast cancer].

Authors:  H H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study.

Authors:  Carolien H M van Deurzen
Journal:  Ann Surg Oncol       Date:  2016-09-02       Impact factor: 5.344

Review 6.  Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  R Colomer; I Aranda-López; J Albanell; T García-Caballero; E Ciruelos; M Á López-García; J Cortés; F Rojo; M Martín; J Palacios-Calvo
Journal:  Clin Transl Oncol       Date:  2017-12-22       Impact factor: 3.405

Review 7.  Clinical validity and clinical utility of Ki67 in early breast cancer.

Authors:  Hans Kreipe; Nadia Harbeck; Matthias Christgen
Journal:  Ther Adv Med Oncol       Date:  2022-09-08       Impact factor: 5.485

8.  Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer?

Authors:  Andrew Evans; Petra Rauchhaus; Patsy Whelehan; Kim Thomson; Colin A Purdie; Lee B Jordan; Caroline O Michie; Alastair Thompson; Sarah Vinnicombe
Journal:  Breast Cancer Res Treat       Date:  2013-12-04       Impact factor: 4.872

9.  Association of conventional ultrasound, elastography and clinicopathological factors with axillary lymph node status in invasive ductal breast carcinoma with sizes > 10 mm.

Authors:  Hui Liu; Guang Xu; Ming-Hua Yao; Huan Pu; Yan Fang; Li-Hua Xiang; Rong Wu
Journal:  Oncotarget       Date:  2017-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.